Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Pacific Biosciences of California, Inc. (“PacBio” or the “Company”) (Nasdaq: PACB).
Request more information now by clicking here:
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) contrary to the Company’s claim that the
system it used for DNA sequencing had a “market dominating” 99.3% base calling accuracy rate, the system’s raw-read accuracy rate was in fact only between 80% and 84%; (2) as a result of PacBio’s inefficient
system, potential customers would be forced to sacrifice long read length time to obtain increased raw-read accuracy in DNA sequencing; (3) numerous bugs and flaws in PacBio’s
system caused it to crash frequently; and (4) owing to the aforementioned problems, PacBio’s
system was receiving significant negative feedback.
As news of these hidden facts gradually reached the market, PacBio’s share price has declined dramatically since the Company’s IPO. Where PacBio shares were trading at $16.44 on October 27, 2010, they closed at $2.82 on December 1, 2011 – a decline of 82.8%.
If you purchased PacBio securities and would like to discuss your legal rights, visit
. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to
. Faruqi & Faruqi, LLP also encourages anyone with information regarding PacBio conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (
). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential matter.